BNTX·Healthcare·Biotech
BioNTech Oncology Faces $1B Buyback Warning Before ASCO
Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience? Maik Kemper Editor…
Biotech
BNTX·Healthcare·Biotech
REGN·Healthcare·Biotech
Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative? Maik…
MRNA·Healthcare·Biotech
Moderna Hantavirus +12% Rally: Can The Surge Last?
Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story? Maik…
AMGN·Healthcare·Biotech
Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…
CRSP·Healthcare·Biotech
CRISPR Therapeutics Pipeline +3.2%: Cardiology Boom Risk
Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor…
BNTX·Healthcare·Biotech
BioNTech Leadership Change: -17.9% Crash After Billion-Euro Loss
Can BioNTech’s surprise leadership change and deepening losses turn a Covid-era star into a long-term oncology value play or a…
MRNA·Healthcare·Biotech
Moderna Patent Settlement +11.3% Surge: Is the $2.25B Hit Worth the Clarity?
Does Moderna’s billion‑dollar patent peace deal finally clear the runway for its mRNA pipeline—or just cap the upside? Moderna Patent…